Clene to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Clene Inc. (Nasdaq: CLNN), a leading biopharmaceutical company dedicated to transforming the treatment of neurodegenerative diseases, has announced its upcoming participation in the H.C. Wainwright 27th Annual Global Investment Conference scheduled for September 8-10, 2025, in New York City. Clene, along with its wholly owned subsidiary Clene Nanomedicine Inc., will present virtually on September 5, 2025, and will also conduct one-on-one investor meetings during the event.

Specializing in conditions such as amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), Clene is at the forefront of developing innovative therapies that focus on enhancing mitochondrial health and preserving neuronal function. Their flagship investigational product, CNM-Au8®, is a first-in-class treatment designed to improve the survival and function of central nervous system cells through targeted mechanisms that enhance mitochondrial function and activate the NAD pathway, all while reducing oxidative stress. This positions Clene uniquely in the biopharmaceutical landscape, addressing critical unmet needs in neurodegenerative disease management.

The company has its headquarters in Salt Lake City, Utah, with additional R&D and manufacturing facilities located in Maryland. Investors interested in learning more about Clene’s innovative approaches and plans are encouraged to access the presentation via Clene's website and can arrange for one-on-one discussions through their H.C. Wainwright contacts.

For further engagement, investor inquiries can be directed to Kevin Gardner at LifeSci Advisors. Clene continues to push boundaries in neurodegenerative disease treatment, making it a noteworthy entity in the biopharmaceutical field as it seeks to revolutionize patient care through scientific advancement. For more details, visit Clene’s website, where the presentation and additional updates will be available.

Clene Inc. (Nasdaq: CLNN) is gearing up to participate in the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10, 2025. This event could serve as a significant platform for the company as it seeks to advance its innovative therapeutic options for neurodegenerative diseases, particularly with its investigational drug CNM-Au8®.

As Clene presents at one of the premier investment conferences, investors should take note of a few key factors. First, the focus of Clene’s research on mitochondrial health in the context of neurodegeneration positions it uniquely in a field that is increasingly in demand. Given the rising prevalence of diseases such as amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), innovative solutions could capture significant market interest.

The company's strategy of emphasizing mitochondrial function and addressing oxidative stress aligns with current trends in biopharmaceuticals that prioritize cellular health. If CNM-Au8® shows promising results in its ongoing clinical trials, the therapeutic’s potential could drive up Clene's stock price and bolster investor confidence.

Moreover, with the company hosting 1x1 investor meetings at the conference, there exists an opportunity for direct engagement with institutional investors. This could translate into more substantial investment backing, contingent on the clarity and efficacy of Clene’s presented data.

Lastly, investors should keep an eye on the virtual presentation, available on September 5, 2025, ahead of the conference, to gauge the company’s communication and strategic vision. Positive reception at this conference could set a bullish tone for Clene moving forward.

In conclusion, as Clene prepares for this event, it represents a critical juncture that may influence investor sentiment and stock performance. Investors should assess the implications of the insights shared at the conference closely.